Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional Bleomycin vs 5-FU + TAC for Keloids
NCT07201766Not yet recruiting
- Sponsor
- King Edward Medical University
- Start
- Dec 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of bleomycin in keloid (2 arms), sponsored by King Edward Medical University. Primary endpoints: Efficacy in terms of POSAS SCAR SCALE at 12 weeks and Efficacy of intralesional bleomycin and combination... comparing scar reduction... POSAS scale at 4 months. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
bleomycin
03
Conditions
keloid
Beyond the preview
Go deeper on NCT07201766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07201766.